Dose screening in FDB MedKnowledge™ Canada uses patient-specific data from within the electronic health record to verify appropriate drug dosing for patients with chronic kidney disease
Online, November 16, 2016 (Newswire.com) - SOUTH SAN FRANCISCO, Calif.--FDB (First Databank, Inc.), the leading provider of clinical drug knowledge that improves medication-related decisions and patient outcomes, today announced the company's dosing modules in FDB MedKnowledge Canada can now perform renally-adjusted dose screening for patients with chronic kidney disease within the electronic health record (EHR) workflow. This feature, already present within the US drug knowledge bases, expands upon FDB's comprehensive clinical decision support modules for drug dosing in Canadian markets by extending the capabilities to include renal dose screening.
FDB introduces drug dose screening for renally-impaired patients in Canadian MedKnowledge base #HITsm #EHR #HealthIT
There is a growing number of patients for whom chronic kidney disease represents a risk factor for death and cardiovascular-related morbidity. Researchers using data from the Canadian Health Measures Survey have determined the prevalence of chronic kidney disease is approximately 12.5%, representing about three million Canadian adults. Renal disease alters the effects of many drugs and their potential toxicity. Many of these changes are predictable and can be mitigated more efficiently by altering drug doses using EHR-collected patient data.
FDB MedKnowledge Canada renal dose screening leverages EHR-collected patient data such as age, weight, body surface area and renal function as therapeutic inputs to automatically determine that the medication order is within the acceptable range for the patient. This new capability for dose screening also provides clinicians with access to current literature on dosing adjustments in renal impairment via drug-specific monographs that help guide drug dosing decisions.
"We are pleased to now offer this drug dosing capability to our robust clinical decision support in FDB MedKnowledge Canada," said Chuck Tuchinda, MD, MBA, president FDB. "We know that getting drug dosing right for patients with chronic kidney disease is extremely difficult and having an automated method for clinical screening of renally-adjusted doses will help improve patient safety through the reduction in medication errors while improving patient care overall for this patient population."
About FDB
FDB, part of the Hearst Health network, is the leading provider of drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into actionable, targeted, and effective solutions that help improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit www.fdbhealth.com or follow us on Twitter and LinkedIn.
About Hearst Health
The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health International, Hearst Health Ventures and the Hearst Health Innovation Lab (www.hearsthealth.com). The mission of the Hearst Health network is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person's health journey. Each year in the U.S., care guidance from the Hearst Health network reaches 84 percent of discharged patients, 177 million insured individuals, 47 million home health visits, and 4 billion prescriptions.
©2016 First Databank, Inc. Part of the Hearst Health network. All trademarks mentioned herein are the properties of their respective owners.
Share: